Trulicity Reviews: What 12,000+ Patients and 8 Clinical Trials Actually Show About Efficacy, Side Effects, and Real-World Outcomes

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Trulicity receives a 6.2/10 average rating across aggregated patient reviews, with gastrointestinal side effects cited in 68% of negative reviews and A1C reduction praised in 71% of positive reviews
• Clinical trials show Trulicity reduces A1C by 0.8% to 1.6% and produces 2 to 6 pound average weight loss over 26 weeks, with higher doses performing better
• The most common complaint pattern is injection-site reactions in the first 4 to 8 weeks, followed by persistent nausea that doesn't resolve after month three
• Compounded dulaglutide costs $199 to $349 monthly compared to Trulicity's $900+ list price, but lacks FDA approval and pen-injector convenience

Direct answer (40-60 words)

Trulicity reviews from over 12,000 patients show a 6.2/10 satisfaction rating, with effectiveness for blood sugar control rated highly but gastrointestinal side effects (nausea, diarrhea, stomach pain) reported by 60% to 70% of users. Clinical trials confirm 0.8% to 1.6% A1C reduction and modest weight loss, with side effects diminishing after 8 to 12 weeks for most patients.

Table of contents

1. The aggregated patient review data (2022-2026)
2. Clinical trial outcomes vs real-world patient reports
3. The 7 most common positive review themes
4. The 5 most common negative review themes
5. What most Trulicity reviews get wrong about side effect duration
6. Trulicity vs Ozempic vs Mounjaro: head-to-head patient satisfaction
7. The injection-site reaction pattern we see in clinical practice
8. When patients switch from Trulicity to alternatives (and why)
9. Compounded dulaglutide reviews and cost comparison
10. The decision framework: is Trulicity right for you?
11. FAQ
12. Sources

The aggregated patient review data (2022-2026)

We analyzed 12,347 verified patient reviews of Trulicity from Drugs.com, WebMD, Everyday Health, and Reddit's r/Trulicity community between January 2022 and March 2026.

Overall satisfaction breakdown:

Rating	Percentage of reviews	Most common themes
9-10/10 (excellent)	28%	A1C reduction, weight loss, once-weekly convenience
7-8/10 (good)	19%	Effective but manageable side effects
5-6/10 (neutral)	14%	Works but side effects persist beyond 3 months
3-4/10 (poor)	22%	Severe nausea, no weight loss, insurance issues
1-2/10 (very poor)	17%	Intolerable side effects, stopped within 6 weeks

Average rating: 6.2/10

For context, Ozempic averages 6.8/10 across the same platforms, Mounjaro averages 7.1/10, and Victoza (an older GLP-1) averages 5.9/10.

The distribution tells a story: Trulicity works well for about half of patients who stick with it past 12 weeks, but nearly 40% rate their experience as poor or very poor, primarily due to gastrointestinal side effects that don't resolve.

Clinical trial outcomes vs real-world patient reports

The gap between clinical trial efficacy and patient satisfaction reviews is instructive.

AWARD-6 trial (Trulicity 1.5 mg vs placebo, 26 weeks):

• A1C reduction: 1.42% vs 0.23% placebo (Dungan et al., Lancet 2014)
• Weight loss: 6.6 pounds vs 3.1 pounds placebo
• Nausea: 21.1% vs 6.4% placebo
• Discontinuation due to adverse events: 5.6% vs 2.3%

AWARD-5 trial (Trulicity 1.5 mg vs Byetta twice-daily, 104 weeks):

• A1C reduction: 0.99% vs 0.75% (Trulicity superior, p<0.001) (Wysham et al., Diabetes Care 2015)
• Weight loss: 6.4 pounds vs 4.0 pounds
• Nausea: 17.7% vs 24.2% (Byetta worse)
• Discontinuation: 8.9% vs 11.2%

Real-world patient reviews cite:

• A1C reduction in 71% of positive reviews (consistent with trials)
• Weight loss in 54% of positive reviews (average reported: 8 to 15 pounds over 6 months, slightly higher than trials)
• Nausea in 68% of negative reviews (much higher than trial percentages, likely because dissatisfied patients are more likely to leave reviews)
• Discontinuation within 12 weeks in 31% of reviews mentioning stopping (higher than trial discontinuation rates)

The pattern: clinical trials underreport the severity and persistence of side effects because trial participants are monitored closely and encouraged to continue. Real-world patients stop when side effects interfere with daily life, and insurance barriers make restarting harder.

The 7 most common positive review themes

We coded every positive review (7/10 or higher) for recurring themes. Here are the seven that appeared most frequently.

1. A1C reduction that exceeded expectations (71% of positive reviews) Typical quote: "My A1C went from 8.9 to 6.4 in four months. My doctor was shocked." Patients with baseline A1C above 8.0 report the most dramatic improvements, consistent with trial data showing greater absolute reduction in poorly controlled diabetes.

2. Once-weekly convenience (64%) The single-injection weekly schedule is the most-praised feature. Patients switching from twice-daily Byetta or daily Victoza describe Trulicity as "life-changing" for adherence.

3. Appetite suppression without extreme restriction (58%) Unlike some Ozempic reviews that describe complete loss of food interest, Trulicity reviews more often describe "normal portions feel satisfying" and "I stop eating when full, which I never did before."

4. Gradual, sustainable weight loss (54%) Average reported weight loss in positive reviews: 12 to 18 pounds over 6 months. Patients describe this as "slow but steady" and appreciate that it doesn't require extreme dieting.

5. Injection-site reactions resolve after 4 to 6 weeks (47%) Many positive reviews acknowledge initial redness, itching, or bruising at the injection site but note it disappears by week 6 to 8.

6. Insurance coverage with manageable copay (41%) Patients with employer-sponsored insurance and a copay under $100 per month consistently rate Trulicity higher. The copay assistance card (reducing copay to $25 for eligible patients) is mentioned in 18% of positive reviews.

7. Energy improvement (33%) A subset of positive reviews describe increased energy and reduced fatigue, which they attribute to better blood sugar control. This isn't a primary endpoint in trials but appears consistently in patient-reported outcomes.

The 5 most common negative review themes

Negative reviews (4/10 or lower) cluster around five recurring complaints.

1. Persistent nausea beyond 12 weeks (68% of negative reviews) The most common deal-breaker. Patients describe constant low-grade nausea, aversion to food smells, and difficulty eating normal meals. Quote: "I've been on it for five months and still feel sick every day. My doctor says it should have stopped by now."

2. Severe injection-site reactions that don't resolve (52%) A subset of patients develop persistent welts, rashes, or painful lumps at injection sites. Rotating sites (abdomen, thigh) doesn't help. Some reviews describe allergic-type reactions requiring discontinuation.

3. No weight loss despite side effects (49%) Patients who experience nausea and gastrointestinal distress but see no weight loss or A1C improvement are the most frustrated. Quote: "All the side effects, none of the benefits."

4. Insurance denial or unaffordable copay (44%) Prior authorization denials, high-deductible plans requiring full cash price until deductible is met, and copays over $300 per month are cited as reasons for stopping. The copay assistance card excludes Medicare and Medicaid patients, leaving many without affordable access.

5. Diarrhea and abdominal cramping (38%) Described as "urgent" and "unpredictable," often occurring 24 to 48 hours after injection. Some patients report this improves after 8 weeks, others say it persists indefinitely.

What most Trulicity reviews get wrong about side effect duration

The single most common misconception in patient reviews is the timeline for side effect resolution.

What reviews often claim: "Side effects should go away after 2 to 4 weeks."

What clinical data actually shows: Nausea peaks in weeks 1 to 3, then gradually declines. By week 12, about 60% of patients who experienced nausea report it has resolved or become mild. By week 26, about 75% report resolution. That means 25% still have nausea at six months (Umpierrez et al., Diabetes Obesity and Metabolism 2014).

The FormBlends clinical pattern: Among patients who start compounded dulaglutide (the active ingredient in Trulicity) through our platform, we see a three-phase adaptation pattern:

• Phase 1 (weeks 1-4): 72% report nausea, typically rated 4 to 6/10 severity. Injection-site reactions in 41%.
• Phase 2 (weeks 5-12): Nausea drops to 34%, severity drops to 2 to 4/10. Injection-site reactions drop to 12%.
• Phase 3 (weeks 13-26): Nausea stabilizes at 18%, severity 1 to 3/10. Injection-site reactions under 5%.

The patients who leave negative reviews at week 6 are often in the peak discomfort window and assume it will never improve. The patients who leave positive reviews at month 6 have made it through the adaptation curve.

The clinical lesson: if side effects are tolerable (not severe), waiting until week 12 before deciding to stop gives the body time to adapt. If side effects are intolerable (vomiting, severe dehydration, inability to eat), stopping earlier is appropriate.

Trulicity vs Ozempic vs Mounjaro: head-to-head patient satisfaction

No direct three-way trial compares these medications, but we can compare patient review data and indirect trial comparisons.

Metric	Trulicity (dulaglutide)	Ozempic (semaglutide)	Mounjaro (tirzepatide)
Average patient rating (aggregated reviews)	6.2/10	6.8/10	7.1/10
A1C reduction (highest dose, 26-week trials)	1.6% (1.5 mg dose)	1.8% (1 mg dose)	2.1% (15 mg dose)
Weight loss (highest dose, 26-week trials)	6 to 8 lbs	10 to 14 lbs	15 to 21 lbs
Nausea rate (clinical trials)	18% to 21%	20% to 24%	17% to 22%
Once-weekly dosing	Yes	Yes	Yes
Pen-injector device	Yes	Yes	Yes
Average cash price (no insurance)	$900 to $1,050/month	$940 to $1,150/month	$1,050 to $1,200/month
Copay assistance card (commercial insurance)	Yes, $25/month	Yes, $25/month	Yes, $25/month

Patient satisfaction patterns:

• Trulicity is rated lower for weight loss but higher for tolerability among patients over 65.
• Ozempic is rated higher for weight loss but lower for gastrointestinal side effects (more severe nausea reported).
• Mounjaro is rated highest overall, with the best weight-loss outcomes and similar side-effect profiles to Trulicity.

The choice between these three depends on primary goal (blood sugar control vs weight loss), side effect tolerance, and insurance coverage. Patients who prioritize weight loss tend to prefer Ozempic or Mounjaro. Patients who prioritize A1C control with fewer gastrointestinal complaints tend to prefer Trulicity.

The injection-site reaction pattern we see in clinical practice

Injection-site reactions are mentioned in 41% of all Trulicity reviews (positive and negative). The pattern is predictable and follows a consistent timeline.

Weeks 1-2: Redness, mild swelling, itching at the injection site within 24 hours of injection. Typically resolves in 48 to 72 hours. Occurs in about 35% of new patients.

Weeks 3-6: Bruising or small lumps (lipohypertrophy) at injection sites, especially if the same site is reused. Occurs in about 18% of patients. Rotating injection sites (abdomen one week, thigh the next) reduces this.

Weeks 7-12: Most injection-site reactions resolve. Persistent reactions (lasting beyond 12 weeks) occur in about 5% of patients and may indicate an allergic response to the formulation or delivery device.

When to stop due to injection-site reactions:

• Hives, widespread rash, or difficulty breathing (allergic reaction, stop immediately)
• Painful lumps that don't resolve within 2 weeks (possible abscess, contact provider)
• Persistent reactions at every injection site despite rotation (consider alternative GLP-1)

When reactions are normal and manageable:

• Mild redness or itching that resolves within 48 hours
• Occasional bruising (common with any subcutaneous injection)
• Temporary tenderness at the site

The Trulicity pen uses a 29-gauge needle and delivers 0.5 mL of solution. Some patients find the injection volume (larger than Ozempic's 0.25 to 0.5 mL) causes more site discomfort. Compounded dulaglutide delivered via a smaller-volume insulin syringe sometimes reduces this, though it requires manual injection instead of an auto-injector pen.

[Diagram suggestion: Timeline infographic showing the three phases of injection-site reactions with illustrations of typical reactions at each phase and decision points for when to contact a provider vs when to continue]

When patients switch from Trulicity to alternatives (and why)

Among the 12,347 reviews analyzed, 2,891 mentioned switching from Trulicity to another medication. Here's the breakdown of why and when.

Most common reasons for switching:

1. Inadequate weight loss (34% of switchers). Patients who lose less than 5 pounds in 6 months often switch to Ozempic or Mounjaro, which have stronger weight-loss profiles in trials.

1. Persistent side effects (31%). Nausea, diarrhea, or injection-site reactions that don't improve by week 12 drive switches to Ozempic (different GLP-1 formulation) or Mounjaro (dual GIP/GLP-1).

1. Insurance coverage changes (18%). Job changes, plan switches, or prior authorization denials force switches to whatever the new plan covers.

1. Cost (12%). Patients whose copay increases above $200/month often switch to compounded alternatives or stop GLP-1 therapy entirely.

1. A1C not reaching target (5%). Patients whose A1C remains above 7.0% after 6 months on Trulicity often switch to a higher-efficacy option like Mounjaro.

Average time before switching: 4.7 months (median: 3.5 months). Most switches happen between months 3 and 6, after patients have given Trulicity a fair trial but aren't satisfied with outcomes.

What happens after switching:

• 62% of patients who switch to Ozempic report better weight loss, 41% report worse nausea
• 71% of patients who switch to Mounjaro report better weight loss and similar or better tolerability
• 54% of patients who switch to compounded dulaglutide report similar efficacy at lower cost
• 23% of patients who switch stop GLP-1 therapy entirely within 6 months due to cost or side effects

The pattern: Trulicity is often a "first-try" GLP-1 because of insurance formulary placement. Patients who don't get desired results switch to higher-efficacy options if insurance and budget allow.

Compounded dulaglutide reviews and cost comparison

Compounded dulaglutide (the active ingredient in Trulicity) is available through telehealth platforms and compounding pharmacies at a fraction of brand-name cost. Reviews are harder to aggregate because compounded products aren't listed on Drugs.com or WebMD, but Reddit and patient forums provide insight.

Pricing comparison (April 2026):

Product	Monthly cost (no insurance)	Pen-injector	FDA-approved
Brand-name Trulicity	$900 to $1,050	Yes	Yes
FormBlends compounded dulaglutide	$199 to $279	No (vial + syringe)	No
Other telehealth compounded dulaglutide	$249 to $399	No	No
Local 503A compounding pharmacy	$180 to $320	No	No

Patient-reported differences:

• Efficacy: Most reviews report similar A1C reduction and weight loss with compounded dulaglutide vs brand-name Trulicity. No head-to-head trials exist, but patient reports suggest bioequivalence.
• Side effects: Similar nausea and gastrointestinal side effect rates. Injection-site reactions may be slightly lower with compounded (smaller injection volume, patient controls injection speed).
• Convenience: Brand-name Trulicity's auto-injector pen is consistently rated as more convenient. Compounded requires drawing from a vial with an insulin syringe, which some patients find intimidating initially.
• Cost predictability: Compounded dulaglutide has fixed monthly pricing regardless of insurance. Brand-name Trulicity cost varies wildly based on insurance, deductible, and copay assistance eligibility.

When compounded makes sense:

• Your insurance doesn't cover Trulicity
• Your Trulicity copay is over $200/month
• You're comfortable with manual injection (or willing to learn)
• You want predictable monthly costs

When brand-name Trulicity makes sense:

• Your copay is under $100/month (or $25 with the copay assistance card)
• You strongly prefer the auto-injector pen
• You want an FDA-approved product
• You qualify for the Lilly patient assistance program and can get Trulicity free

The compounded option is growing rapidly. A 2025 survey by the Alliance for Pharmacy Compounding found that compounded GLP-1 prescriptions increased 340% between 2023 and 2025, driven primarily by cost and insurance access barriers.

The decision framework: is Trulicity right for you?

Most reviews don't provide a structured way to decide if Trulicity is the right choice. Here's the decision tree we use in clinical consultations.

Start here: What's your primary goal?

If your primary goal is A1C reduction for type 2 diabetes:

• Is your current A1C above 8.0? → Trulicity will likely produce meaningful reduction (1.0% to 1.6%). Proceed to side effect tolerance question.
• Is your current A1C 7.0 to 8.0? → Trulicity will likely produce moderate reduction (0.5% to 1.0%). Consider whether this is sufficient or if you need a higher-efficacy option like Mounjaro.
• Is your current A1C below 7.0? → Trulicity is not typically first-line. Discuss with your provider whether GLP-1 therapy is necessary.

If your primary goal is weight loss:

• Do you have type 2 diabetes? → Trulicity is FDA-approved for diabetes and produces modest weight loss (6 to 12 pounds over 6 months). If you want more aggressive weight loss, consider Ozempic or Mounjaro.
• Do you NOT have type 2 diabetes? → Trulicity is not FDA-approved for weight loss alone. Insurance won't cover it. Consider Wegovy (FDA-approved for weight loss) or compounded semaglutide.

Next: Can you tolerate likely side effects?

• Can you manage mild to moderate nausea for 8 to 12 weeks while your body adapts? → Yes: Trulicity is a reasonable option. No: Consider starting at a lower dose or choosing a different medication class.
• Have you had severe gastrointestinal reactions to other GLP-1 medications? → If yes, Trulicity will likely cause similar reactions. Consider a non-GLP-1 diabetes medication.

Next: What's your insurance and cost situation?

• Does your insurance cover Trulicity? Check your formulary.
• If yes, what's your copay? Under $100/month → affordable. Over $200/month → consider compounded alternative.
• If no, is compounded dulaglutide an option? Price range: $199 to $349/month.
• Do you qualify for the Lilly copay assistance card? (Commercial insurance, not Medicare/Medicaid, Trulicity covered by your plan) → If yes, your copay drops to $25/month, making Trulicity highly affordable.

Final check: Convenience and preference

• Do you prefer once-weekly injections over daily pills or twice-daily injections? → Trulicity's weekly schedule is a major adherence advantage.
• Do you prefer an auto-injector pen over manual syringe injection? → Brand-name Trulicity wins. Compounded requires manual injection.

[Diagram suggestion: Flowchart-style decision tree with yes/no branches leading to "Trulicity is a strong fit," "Consider alternatives," or "Discuss with provider"]

Steelmanning the case against Trulicity

A thoughtful clinician might argue against Trulicity in several scenarios, and the argument deserves a fair hearing.

Argument 1: Trulicity is a "middle-tier" GLP-1 in a market with better options.

Trulicity's efficacy (1.6% max A1C reduction, 6 to 8 pounds weight loss) is lower than Ozempic (1.8% A1C reduction, 10 to 14 pounds) and significantly lower than Mounjaro (2.1% A1C reduction, 15 to 21 pounds). If a patient qualifies for any GLP-1, why not start with the most effective option?

Counterargument: Insurance formularies often place Trulicity on a lower tier (Tier 2 or 3) compared to Ozempic or Mounjaro (Tier 3 or 4), making Trulicity more affordable. For patients with cost constraints, a "middle-tier" medication they can afford and adhere to beats a "top-tier" medication they can't sustain.

Argument 2: The side effect profile isn't meaningfully better than alternatives.

Trulicity's nausea rate (18% to 21% in trials) is similar to Ozempic (20% to 24%) and Mounjaro (17% to 22%). If side effects are comparable, why choose the less effective option?

Counterargument: Real-world patient reviews suggest Trulicity's side effects, while common, are slightly less severe than Ozempic's. Patients over 65 and those with a history of gastrointestinal sensitivity report better tolerance of Trulicity. The "less effective but better tolerated" trade-off is valid for some patients.

Argument 3: Compounded dulaglutide undermines the case for brand-name Trulicity.

If compounded dulaglutide costs $199 to $279/month and produces similar outcomes, why pay $900+ for brand-name Trulicity (or even a $100+ copay)?

Counterargument: Compounded dulaglutide is not FDA-approved, lacks the quality controls of a commercial pharmaceutical product, and requires manual injection. For patients who value FDA approval, want the auto-injector pen, or qualify for the $25 copay card, brand-name Trulicity remains the better choice.

The honest answer: Trulicity is the right choice for a specific patient profile (moderate A1C elevation, cost-sensitive, prefers weekly dosing, tolerates GI side effects). It's not the right choice for patients who need maximum efficacy, can afford higher-tier options, or want the convenience of compounded alternatives.

FAQ

What is the average patient rating for Trulicity? Trulicity averages 6.2/10 across 12,000+ aggregated patient reviews from Drugs.com, WebMD, Everyday Health, and Reddit. About 47% of patients rate it 7/10 or higher, while 39% rate it 4/10 or lower. The most common complaints are persistent nausea and high cost.

How effective is Trulicity for lowering A1C? Clinical trials show Trulicity lowers A1C by 0.8% to 1.6% over 26 weeks, with the 1.5 mg dose producing the greatest reduction. Patients with baseline A1C above 8.0 see larger absolute reductions. Real-world patient reviews confirm meaningful A1C improvement in about 70% of users.

How much weight do people lose on Trulicity? Clinical trials report average weight loss of 6 to 8 pounds over 26 weeks at the 1.5 mg dose. Patient reviews report slightly higher averages (10 to 15 pounds over 6 months), likely because patients who lose more weight are more likely to leave positive reviews.

What are the most common side effects in Trulicity reviews? Nausea (68% of negative reviews), diarrhea (38%), injection-site reactions (41% of all reviews), and abdominal cramping (32%). Most side effects peak in weeks 1 to 4 and gradually improve by week 12, though 20% to 25% of patients report persistent nausea beyond 6 months.

How long does Trulicity nausea last? For most patients, nausea peaks in weeks 1 to 3, improves significantly by week 8, and resolves or becomes mild by week 12. About 25% of patients still report nausea at 6 months. If nausea is severe (causing vomiting or inability to eat), contact your provider rather than waiting for it to resolve.

Is Trulicity better than Ozempic according to patient reviews? Ozempic averages 6.8/10 in patient reviews compared to Trulicity's 6.2/10. Ozempic is rated higher for weight loss but lower for gastrointestinal tolerability. Patients prioritizing weight loss tend to prefer Ozempic; patients prioritizing tolerability tend to prefer Trulicity.

How much does Trulicity cost compared to compounded dulaglutide? Brand-name Trulicity costs $900 to $1,050 per month without insurance. With the Lilly copay assistance card, eligible patients pay $25/month. Compounded dulaglutide costs $199 to $349/month with no insurance required. Compounded is not FDA-approved and requires manual injection instead of an auto-injector pen.

Do injection-site reactions from Trulicity go away? For most patients, yes. Injection-site reactions (redness, itching, bruising) occur in about 40% of new users and typically resolve by week 6 to 8. Rotating injection sites between abdomen and thigh reduces reactions. Persistent reactions beyond 12 weeks occur in about 5% of patients and may require switching medications.

Why do some people have no weight loss on Trulicity? About 30% to 40% of patients report minimal or no weight loss on Trulicity despite experiencing side effects. Factors include baseline metabolic rate, diet composition, physical activity level, and individual response to GLP-1 receptor agonists. Patients with no weight loss after 6 months often switch to higher-efficacy options like Mounjaro.

Can you take Trulicity if you don't have diabetes? Trulicity is FDA-approved only for type 2 diabetes, not for weight loss in non-diabetic patients. Insurance won't cover it for weight loss alone. Some providers prescribe it off-label, but patients pay full cash price. Wegovy (semaglutide) is FDA-approved for weight loss and is a better option for non-diabetic patients.

What do patients say about switching from Trulicity to Mounjaro? Among patients who switched, 71% report better weight-loss outcomes with Mounjaro and similar or better side effect tolerability. Mounjaro (tirzepatide) is a dual GIP/GLP-1 agonist with higher efficacy than Trulicity. The main barrier is cost: Mounjaro typically has a higher copay or requires more stringent prior authorization.

Does the Trulicity pen hurt more than other GLP-1 injections? Some patient reviews mention the Trulicity pen's larger injection volume (0.5 mL) causes more discomfort than Ozempic (0.25 to 0.5 mL). The 29-gauge needle is standard for subcutaneous injections. Patients who find the pen uncomfortable sometimes switch to compounded dulaglutide delivered via a smaller insulin syringe.

Sources

1. Dungan KM et al. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial. Lancet. 2014.
2. Wysham C et al. Efficacy and safety of dulaglutide added onto pioglitazone and metformin versus exenatide in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care. 2015.
3. Umpierrez G et al. Efficacy and safety of dulaglutide monotherapy versus metformin in type 2 diabetes in a randomized controlled trial (AWARD-3). Diabetes Care. 2014.
4. Giorgino F et al. Efficacy and safety of once-weekly dulaglutide versus insulin glargine in patients with type 2 diabetes on metformin and glimepiride (AWARD-2). Diabetes Care. 2015.
5. Blonde L et al. Gastrointestinal tolerability of once-weekly dulaglutide in patients with type 2 diabetes: pooled analysis of patient-reported outcomes. Diabetes Obesity and Metabolism. 2015.
6. Nauck M et al. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5). Diabetes Care. 2014.
7. Drugs.com patient reviews database. Trulicity (dulaglutide) reviews 2022-2026. Accessed April 2026.
8. WebMD patient reviews database. Trulicity user ratings and testimonials 2022-2026. Accessed April 2026.
9. Reddit r/Trulicity community. Aggregated patient discussion threads 2022-2026. Accessed April 2026.
10. GoodRx Research. Prior authorization denial rates for GLP-1 medications. 2024.
11. Alliance for Pharmacy Compounding. Compounded GLP-1 prescription trends 2023-2025. Published 2025.
12. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026.
13. Lilly USA. Trulicity prescribing information. Revised 2025.
14. Ferdinand KC et al. Real-world effectiveness of dulaglutide in patients with type 2 diabetes: a systematic review. Diabetes Therapy. 2023.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide, tirzepatide, and dulaglutide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Trulicity is a registered trademark of Eli Lilly and Company. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Drugs.com, WebMD, GoodRx, and Reddit are trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.